{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T19:50:48Z","timestamp":1754164248455,"version":"3.41.2"},"reference-count":5,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Dermatol Surg","DS"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1097\/dss.0000000000002563","type":"journal-article","created":{"date-parts":[[2020,8,13]],"date-time":"2020-08-13T16:06:13Z","timestamp":1597334773000},"page":"47-47","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Commentary on A Large, Open-Label, Phase 3 Safety Study of DaxibotulinumtoxinA for Injection in Glabellar Lines"],"prefix":"10.1097","volume":"47","author":[{"given":"Amelia K.","family":"Hausauer","sequence":"first","affiliation":[{"name":"AESTHETX Plastic Surgery and Dermatology, Campbell, California"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,8,11]]},"reference":[{"key":"R2-20250731","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.jaad.2019.06.1313","article-title":"DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2)","volume":"82","author":"Bertucci","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"R3-20250731","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1097\/DSS.0000000000001206","article-title":"Injectable DaxibotulinumtoxinA for the treatment of glabellar lines: a phase 2, randomized, dose-ranging, double-blind, multicenter comparison with OnabotulinumtoxinA and placebo","volume":"43","author":"Carruthers","year":"2017","journal-title":"Dermatol Surg"},{"key":"R4-20250731","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/PRS.0000000000006327","article-title":"DaxibotulinumtoxinA for injection for the treatment of glabellar lines: results from each of two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2)","volume":"145","author":"Carruthers","year":"2020","journal-title":"Plast Reconstr Surg"},{"key":"R5-20250731","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/DSS.0000000000002531","article-title":"DaxibotulinumtoxinA for injection for the treatment of glabellar lines: efficacy results from SAKURA 3, a large, open-label, phase 3 safety study","volume":"47","author":"Fabi","year":"2021","journal-title":"Dermatol Surg"},{"key":"R6-20250731","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/DSS.0000000000002463","article-title":"A large, open-label, phase 3 safety study of DaxibotulinumtoxinA for injection in glabellar lines: a focus on safety from the SAKURA 3 study","volume":"47","author":"Green","year":"2021","journal-title":"Dermatol Surg"}],"container-title":["Dermatologic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/DSS.0000000000002563","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T22:12:25Z","timestamp":1753999945000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/DSS.0000000000002563"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,11]]},"references-count":5,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/dss.0000000000002563","relation":{},"ISSN":["1076-0512","1524-4725"],"issn-type":[{"type":"print","value":"1076-0512"},{"type":"electronic","value":"1524-4725"}],"subject":[],"published":{"date-parts":[[2020,8,11]]}}}